Pharma Business of HIV/AIDS, STDs & STIs

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to increase till $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015. The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, a stringent government regulation for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

    Related Conference of Pharma Business of HIV/AIDS, STDs & STIs

    May 10-11, 2021

    4th Global Experts Meeting on Infectious Diseases

    Singapore City, Singapore
    May 27-28, 2021

    7th Rare Diseases and Orphan Drugs

    Vienna, Austria
    July 19-20, 2021

    13th Global Infections Conference

    Tokyo, Japan
    September 06-07, 2021

    11th World Congress on Rare Diseases and Orphan Drugs

    Berlin, Germany
    October 21-22, 2021

    International Conference on Tropical Diseases and Cure

    Zurich, Switzerland
    November 22-23, 2021

    3rd World Congress on Advancements in Tuberculosis and Lung Diseases

    Singapore City, Singapore
    February 07-08, 2022

    9th International Congress on Infectious Diseases

    Aberdeen, UK

    Pharma Business of HIV/AIDS, STDs & STIs Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in